Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 64 publications
0
3
0
Order By: Relevance
“…Furthermore, even though inflammatory/immune complications are increased among MDS patients [ 65 ], we could not detect any difference in CRP levels between the patients with MDS/MDS-AML and the other patients. The frequency of GVHD (together with the risk of relapse) is regarded as a major challenge in allotransplanted MDS patients [ 81 , 87 ], and recent studies suggest that intensified GVHD prophylaxis should be considered for MDS patients [ 87 , 88 ]. However, our present observations suggest that this possible need for intensification is not due to an increased frequency of pretransplant inflammation among MDS patients.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, even though inflammatory/immune complications are increased among MDS patients [ 65 ], we could not detect any difference in CRP levels between the patients with MDS/MDS-AML and the other patients. The frequency of GVHD (together with the risk of relapse) is regarded as a major challenge in allotransplanted MDS patients [ 81 , 87 ], and recent studies suggest that intensified GVHD prophylaxis should be considered for MDS patients [ 87 , 88 ]. However, our present observations suggest that this possible need for intensification is not due to an increased frequency of pretransplant inflammation among MDS patients.…”
Section: Discussionmentioning
confidence: 99%
“…1 The median age of diagnosis is 70 years. 4 Refractory cytopenia is the major cause of morbidity and mortality in patients with MDS. 5…”
Section: Introductionmentioning
confidence: 99%
“…Patients with transfusion dependency (≥ 2 units of blood per month), significant cytopenias (platelets < 30 × 10 9 /l, neutrophils < 0.3 × 10 9 /l) or adverse cytogenetics should be considered for a transplant, possibly before iron overload occurs, or after failure of ESA or lenalidomide treatment, in particular if TP53mut coexists with del(5q). Fibrosis should also prompt transplant consideration at an early stage. Transplantation in higher risk MDS: current recommendations indicate upfront transplantation if BM blasts are 5–10%, and HMA before transplantation should be given if BM blasts are >10%, with as few cycles as possible to minimise subsequent post‐transplant toxicities and TRM, as evidenced by the VIDAZA ALLO trial 9,10 Mutation analysis: patients potentially presented as candidates for transplantation should be screened for mutations of the TP53 , RAS , JAK2 , DNMT3A , TET2 , ASXL1 and RUNX1 genes, which correlate with poorer outcomes.…”
mentioning
confidence: 99%